Functionally, TAMs support MM proliferation (by secreting IL6), angiogenesis (by secreting VEGF, CCLs, matrix metalloproteinases (MMPs)), and immunosuppression (by secreting IL10, TGFβ, indoleamine 2,3-dioxygenase (IDO) and inhibiting IL12 and TNFα production) in the tumor microenvironment [93,94]. The gene discussed is VEGFA; the disease is Miyoshi myopathy.